These studies will not only reveal additional mechanisms critically important for future clinical application, but they will also facilitate finding novel combination therapies that are more specific to targeting IL-10 or its downstream pathways, and thus able to exclusively enhance the immunostimulatory anti-tumor effects while excluding the immunosuppressive functions of IL-10. This evidence concerns the gene IL10 and neoplasm.